BioXpress Therapeutics SA is a premier partner for high-quality biosimilar monoclonal antibodies for unmet need indications such as cancer, inflammation and autoimmunity, including adaptive immunity. We have made a commitment to be your partner of choice for the full development of your biosimilar biol...
The article reports on the agreement entered by generic drug developer, AET Biotechnology Ltd., with biotechnology company, BioXpress Therapeutics SA, in developing the monoclonal antibody (MAb) biosimilars. It states that AET Biotech will be responsible for providing further investment in the long ...